We studied the scientific literature and disease guidelines in order to summarize the clinical utility of genetic testing for Bardet-Biedl syndrome (BBS). The disease has autosomal recessive inheritance, a prevalence varying from one in 13 500 to one in 160 000, and is caused by mutations in the ARL6,
Moreover it is well accepted that, in addition to variants in a known gene, variants in an heterozygous state at a different locus may affect the phenotype (10) .
Pathogenic variants may consist in small intragenic deletions/ insertions, as well as splice-site, missense and nonsense variants and also deep intronic variants (such as c.2991+1655A>G in CEP290); Exon or whole-gene duplications/deletions have also been reported (1) .
Aims of the test
• To determine the gene defect responsible for the pathology • To confirm clinical diagnosis of the disease • To determine carrier status for the disease.
Test characteristics Expert centers/Published guidelines
The test is listed in the Orphanet database and is offered by 24 accredited medical genetic laboratories in the EU, and in the GTR database, offered by 22 accredited medical genetic laboratories in the US.
The guidelines for clinical use of the test are described in "Genetics home reference" (ghr.nlm.nih.gov) and "Gene reviews".
Test strategy
A multi-gene NGS panel is used for the detection of nucleotide variations in coding exons and flanking introns known genes. Potentially causative variants and region with low coverage are Sanger-sequenced. MLPA is used to detect duplications and deletions in CEP290. Sanger sequencing is also used for family segregation studies.
The test identifies variations in known causative genes in patients suspected to have BBS. To perform molecular diagnosis, a single sample of biological material is normally sufficient. This may be 1 ml blood in a sterile tube with 0.5 ml K3EDTA or 1 ml saliva in a sterile tube with 0.5 ml ethanol 95%. Sampling rarely has to be repeated. Gene-disease associations and interpretation of genetic variants are rapidly developing fields. It is therefore possible that the genes mentioned in this note may change as new scientific data is acquired. It is also possible that genetic variants today defined as of "unknown or uncertain significance" may acquire clinical importance. A pathogenic variant is known to be causative for a given genetic disorder based on previous reports or predicted to be causative based on the loss of protein function or expected significant damage to protein or protein/protein interactions. In this way it is possible to obtain a molecular diagnosis in new/ other subjects, establish the risk of recurrence in family members and plan preventive and/or therapeutic measures.
Genetic test results

Inconclusive
Detection of a variant of unknown or uncertain significance: a new variation and/or without any evident pathogenic significance or with insufficient or significant conflicting evidence to indicate it is likely benign or likely pathogenic for a given genetic disorder. In these cases, it is advisable to extend testing to the patient's relatives in order to assess variant segregation and clarify its contribution. In some cases it could be necessary to perform further examinations/tests or to do a clinical reassessment of pathological signs.
Negative
The absence of variations in the genomic regions investigated does not exclude a clinical diagnosis but suggests the possibility of:
• sequence variations in gene regions not investigated by this test, such as regulatory regions (5' and 3' UTR) and deep intronic regions; • variations in other genes not investigated by the present test;
• alterations that cannot be identified by sequencing, such as large rearrangements that cause loss (deletion) or gain (duplication) of extended gene fragments.
Unexpected
Unexpected results may come out from the test, for example information regarding consanguinity; absence of family correlation or the possibility of developing genetically based diseases.
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Risk for progeny
Autosomal recessive transmission needs that both healthy carrier parents transmit their disease variant to his/her children. In this case, the probability of having an affected boy or girl is therefore 25%. Although a second locus effect is described, even in the presence of the so-called "triallelic" genetic asset, the risk should be evaluated as for a pure recessive disease (11) .
Limits of the test
The test is limited by current scientific knowledge regarding the genes and disease.
Analytical sensitivity (proportion of positive tests when the genotype is truly present) and analytical specificity (proportion of negative tests when the genotype is not present) 
Prescription appropriateness
The genetic test is appropriate when: a) the patient meets the diagnostic criteria for the disease; b) the genetic test has diagnostic sensitivity greater than or equal to other published tests.
Clinical utility
Clinical management Utility
Confirmation of clinical diagnosis yes
Differential diagnosis yes
Access to clinical trial (13) yes
Couple risk assessment yes
